For Doctors in a Hurry
- Researchers investigated if iatrogenic cerebral amyloid angiopathy differs from sporadic forms in amyloid burden, cerebrospinal fluid biomarkers, and genetic risk.
- This single-center cross-sectional study evaluated 24 patients with iatrogenic disease and 71 patients with the sporadic condition.
- Iatrogenic cases showed higher amyloid deposition (median 57.3 versus 30.5 Centiloids; p=0.0026) and significantly lower apolipoprotein E epsilon 4 frequency.
- The authors concluded that iatrogenic disease follows a divergent propagation mechanism compared to the more common sporadic form.
- These findings suggest that iatrogenic transmission should be suspected in younger patients presenting with atypical biomarker profiles.
The Emerging Challenge of Iatrogenic Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) is a significant cause of small vessel disease, often manifesting as intracerebral hemorrhage, transient neurological episodes, or cognitive decline [1, 2]. While typically associated with advanced age and the apolipoprotein E (APOE) ε4 allele, CAA is increasingly understood as a heterogeneous condition with multiple pathological drivers [3, 4]. Advanced neuroimaging, particularly amyloid positron emission tomography (PET), is crucial for distinguishing CAA from other conditions like Alzheimer’s disease [5, 6]. However, the identification of iatrogenic cases linked to historical medical procedures has raised urgent questions about whether this mode of exogenous amyloid transmission produces a distinct clinical and biological phenotype [7, 8]. A recent study provides a detailed comparison of amyloid burden and fluid biomarkers between these iatrogenic and sporadic forms, offering new clarity on their divergent pathologies.
Comparing Iatrogenic and Sporadic Cohorts
To delineate the features of iatrogenic versus sporadic disease, a single-center, cross-sectional analysis was conducted between 2021 and 2024. The SENECA study (ClinicalTrials.gov Identifier: NCT04204642) enrolled 95 adults who met diagnostic criteria for probable CAA and had undergone both amyloid PET and cerebrospinal fluid (CSF) assessment. The cohort consisted of 24 patients with iatrogenic CAA (iCAA) and 71 with sporadic CAA (sCAA). A key demographic difference was immediately apparent: the median age of the iCAA group was 56.5 years, substantially younger than the 70-year median age in the sCAA group, highlighting the different natural histories of these conditions. To standardize imaging data, amyloid burden was quantified using Centiloid scaling, a method that converts PET results from different radiotracers (in this case, 18F-flutemetamol or 18F-florbetaben) into a uniform 0 to 100 scale, allowing for direct comparison of amyloid density across patients. In parallel, CSF biomarkers were measured using Lumipulse assays, an automated and highly precise immunoassay technique. The panel included amyloid-beta 42 (Aβ42), amyloid-beta 40 (Aβ40), the Aβ42/Aβ40 ratio, phosphorylated tau 181 (p-tau181), and total tau (t-tau). This dual-modality approach aimed to create a comprehensive neurobiological profile for each disease form.
Quantifying Amyloid Burden and Genetic Risk
The study's primary imaging analysis revealed a stark difference in amyloid load between the two groups. Patients with iCAA demonstrated a significantly higher amyloid deposition, with a median Centiloid value of 57.3 compared to 30.5 in the sCAA group (p = 0.0026). To confirm that this finding was not simply a consequence of demographic differences, the researchers performed a multivariable regression analysis. After adjusting for age and sex, the iCAA diagnosis remained independently associated with an increase of 34.99 Centiloid units (95% CI 15.25 to 54.74; p = 0.001). This robust association suggests that the mechanism of amyloid accumulation in iatrogenic cases may be more aggressive or follow a distinct pathological pathway compared to the slower, age-related process in sporadic disease. The genetic profiles of the cohorts further underscored their differences. The APOE ε4 allele, a well-established genetic risk factor for sporadic amyloid deposition, was found to be a minor contributor in the iatrogenic form. The study reported that the frequency of APOE ε4 was markedly lower in the iCAA group (4.5%) compared to the sCAA group (34.2%). For clinicians, this finding is critical: a negative APOE ε4 status does not diminish the likelihood of CAA in a patient with a high amyloid burden and a history of neurosurgical intervention, especially at a younger age of onset.
Divergent Biomarker Correlations and Pathophysiology
The investigation into CSF biomarkers uncovered a fundamental divergence in the pathophysiology of iatrogenic and sporadic CAA. In patients with sCAA, the findings aligned with the established biological model of amyloidosis: Centiloid values correlated inversely with CSF Aβ42 levels and the Aβ42/Aβ40 ratio. This inverse relationship is expected, as higher amyloid deposition in cerebral blood vessels (measured by PET) leads to a corresponding depletion of soluble amyloid-beta from the CSF. This reflects a process of amyloid sequestration within the brain. However, this classic biomarker signature was absent in the iatrogenic cohort. The researchers found no significant correlation between Centiloid values and CSF Aβ42 or the Aβ42/Aβ40 ratio in patients with iCAA. This disconnect suggests that the dynamics of amyloid clearance and deposition in iCAA are distinct from those in the sporadic form. The findings support a divergent mechanism of amyloid propagation, likely driven by the exogenous introduction of amyloid seeds during a past medical procedure, which may lead to a more aggressive or localized deposition not fully reflected by global CSF changes. For the practicing physician, these results establish iCAA as a distinct clinicopathological entity. The absence of typical correlations between imaging and CSF biomarkers means clinicians should maintain a high index of suspicion for iCAA in younger patients with high amyloid burden, even if their CSF profile or APOE genotype does not fit the classic pattern of sporadic disease.
References
1. Jennings B, Sharma S, Stewart A, et al. Abstract WP097: A Multidisciplinary Clinic Model Provides Coordinated Care, Biomarker Integration, and Clinical Trial Access in Cerebral Amyloid Angiopathy. Stroke. 2026. doi:10.1161/str.57.suppl_1.wp097
2. Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia. Stroke. 2011. doi:10.1161/str.0b013e3182299496
3. Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review. Alzheimer s Research & Therapy. 2020. doi:10.1186/s13195-020-00712-4
4. Zedde M, Piazza F, Pascarella R. Positron Emission Tomography in Cerebral Amyloid Angiopathy: A Scoping Review. Applied Sciences. 2025. doi:10.3390/app15073973
5. Dondi F, Bertoli M, Lucchini S, Cerudelli E, Albano D, Bertagna F. PET imaging for the evaluation of cerebral amyloid angiopathy: a systematic review. Clinical and translational imaging. 2022. doi:10.1007/s40336-022-00511-x
6. Theodorou A, Melanis K, Athanasaki A, et al. Cerebral amyloid angiopathy and amyloid load distribution detected on amyloid–positron emission tomography: A systematic review and meta-analysis. European Stroke Journal. 2025. doi:10.1093/esj/23969873251349657
7. Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduction and Targeted Therapy. 2023. doi:10.1038/s41392-023-01484-7
8. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zloković BV. Blood-Brain Barrier: From Physiology to Disease and Back. Physiological Reviews. 2018. doi:10.1152/physrev.00050.2017
